Ann: Noxopharm Announces Leadership Transition, page-3

Graham Kelly made sure that the clinical trial program logistics for DARRT, IONIC and CEP were in place before his transition to "consultant" took effect. In his new role, I expect him to be able to concentrate on patent matters - which is virtually a full-time job - and major projects such as the HIMR License.

Noxopharm represents his life's work, so there is no way Graham will have taken this step if he thought the Company would suffer. This change means that Noxopharm will have a new 'face' as CEO, and that Graham will have more time to focus on big-ticket items.